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Abstract: Worldwide, up to 20% of children and adolescents experience mental disorders, which are the
leading cause of disability in young people. Research shows that serum zonulin levels are associated
with increased intestinal permeability (IP), affecting neural, hormonal, and immunological pathways.
This systematic review and meta-analysis aimed to summarize evidence from observational studies on
IP in children diagnosed with mental disorders. The review follows the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic search of the Cochrane
Library, PsycINFO, PubMed, and the Web of Science identified 833 records. Only non-intervention
(i.e., observational) studies in children (<18 years) diagnosed with mental disorders, including a relevant
marker of intestinal permeability, were included. Five studies were selected, with the risk of bias assessed
according to the Newcastle–Ottawa scale (NOS). Four articles were identified as strong and one as moderate,
representing altogether 402 participants providing evidence on IP in children diagnosed with attention
deficit and hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive–compulsive
disorder (OCD). In ADHD, elevated serum zonulin levels were associated with impaired social functioning
compared to controls. Children with ASD may be predisposed to impair intestinal barrier function,
which may contribute to their symptoms and clinical outcome compared to controls. Children with ASD,
who experience gastro-intestinal (GI) symptoms, seem to have an imbalance in their immune response.
However, in children with OCD, serum zonulin levels were not significantly different compared to controls,
but serum claudin-5, a transmembrane tight-junction protein, was significantly higher. A meta-analysis
of mean zonulin plasma levels of patients and control groups revealed a significant difference between
groups (p = 0.001), including the four studies evaluating the full spectrum of the zonulin peptide family.
Therefore, further studies are required to better understand the complex role of barrier function, i.e., intestinal
and blood–brain barrier, and of inflammation, to the pathophysiology in mental and neurodevelopmental
disorders. This review was PROSPERO preregistered, (162208).
Keywords: children; adolescents; intestinal permeability; mental disorders; zonulin; haptoglobin; attention
deficit and hyperactivity disorder (ADHD); autism spectrum disorder (ASD); obsessive–compulsive
disorder (OCD); systematic review; meta-analysis
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1. Introduction
Worldwide, up to 20% of children and adolescents experience mental, behavioral,
and neurodevelopmental disorders, and these are the leading cause of disability in young people [1,2].
The etiology of most mental disorders, including behavioral and neurodevelopmental disorders,
is unknown, but genetic factors, biochemical imbalances, and reactions to environmental stressors seem to
play a role [3,4]. Known mental disorders in children and adolescents are, e.g., ADHD, anxiety disorders,
OCD, ASD, depressive disorders, bipolar disorder (BD) and schizophrenia, and co-morbidity is frequently
seen. Characteristics of mental disorders such as ADHD, ASD, and OCD are partly overlapping,
i.e., poor academic performance, impaired social skills, hyperactivity, and impulsive behavior. The interplay
between mental disorders, IP, and the intestinal microbiota has become a rapidly growing area of
research. Increased IP has been examined with regard to emotional, behavioral, and neurodevelopmental
disorders such as ADHD, ASD, major depressive disorders (MDD), obsessive–compulsive disorder (OCD),
and schizophrenia [5–14].
The digestive tract is the body’s largest interface with the external environment. The function
of the intestines is to be selectively permeable by allowing absorption of needed nutrients from the
lumen, through the intestinal cells, into the intestinal milieu and the circulation as well as preventing
the transfer of harmful entities by barrier function [15]. Inherent to the rationale of a gastro-intestinal
tract in the pathogenesis of mental disorders is the model of IP of the intestinal barrier [16,17].
Zonulin is a family of structurally and functionally related peptides whose archetype member
is pre-haptoglobin-2. Zonulin family peptides (from now on referred to as zonulin) are the only
known physiologic modulator of intercellular tight junctions described so far and affect mechanisms
that regulate the intestinal epithelial paracellular pathway [18–20]. Zonulin seems to be the primary
modulator for regulating permeability in both gut–blood and blood–brain barriers and has been used as
a clinical indicator of intestinal permeability [17]. Zonulin is also a potential inflammatory marker and
contributes to intestinal innate immunity. Increased IP coinciding with inflammation has been described
in mental disorders in adults [21–26]. Zonulin has been associated with low-grade inflammation
and autoimmune diseases, as well as ASD, which might have an autoimmune component [6,27,28].
Children with ASD have been found to display an increased immune reactivity against proteins
such as gluten, found in certain types of grain, potentially as a result of increased IP [7,29,30].
Furthermore, in ASD, higher serum zonulin has been associated with social impairment compared to
controls [5].
As in numerous gastro-intestinal (GI) disorders, chronic inflammation has been found in mental
disorders [31]. Loss of the intestinal barrier function leads to an increased influx of dietary and microbial
factors and may contribute to the progression of chronic inflammatory disorders [32]. Recent studies
show that inflammation seems to play a role in the pathogenesis of depression, at least for a subset
of individuals [33]. The pediatric literature also demonstrates mutually influencing bidirectional
pathways between inflammation and depression [34]. Children with higher levels of interleukin 6
(IL-6) and C-reactive protein (CRP) are, for example, more likely to be depressed later in life [35].
Furthermore, type 2 tissue transglutaminase (TG2), an autoantigen in celiac disease, has been
associated with various diseases in humans, i.e., inflammation, cancer, fibrosis, cardiovascular
disease, and neurodegenerative diseases [36]. Moreover, the presence of antibodies against gluten
has been described in gluten sensitivity, a common complaint in subgroups of ASD subjects [7].
However, transglutaminase 6 (TG6) is sensitive and specific in gluten ataxia. This extraintestinal
manifestation can cause neurologic disorders, i.e., cerebellar gluten ataxia and peripheral neuropathy,
and has been reported in schizophrenia, cerebral palsy, and gluten neuropathy [37]. The role of
inflammation in the development of mental disorders needs further investigation.
The commensal microorganisms living within the gut lumen, i.e., the intestinal microbiota,
can affect both the host’s physiology and pathology [38,39]. Recent studies reveal that an imbalance of
the intestinal microbiota, i.e., intestinal dysbiosis [40], can lead to loss of barrier function and increase
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IP and is thought to be one of the mechanisms by which intestinal microbiota may affect the central
nervous system (CNS).
Recently, a similar permeability mechanism related to the CNS and the blood–brain barrier has
been described [11]. Claudin-5, a transmembrane tight-junction protein, is expressed in the blood–brain
barrier and plays a crucial role in maintaining the integrity of the brain endothelial barrier, and changes
in this function may contribute to enhanced permeability of the endothelial barrier of the brain [9,11].
Increased expression of claudin-5 has been associated with mental disorders. Serum claudin-5 levels
have been found significantly higher in OCD subjects [9]. Furthermore, an aberrant pattern of claudin-5
immunoreactivity has been observed in schizophrenia subjects [10].
Gut–brain axis (GBA) involves bidirectional communication between the brain and the intestinal
tract, linking the enteric and central nervous systems, which affects mental health, impacting both
mood and behavior [41]. The GBA is considered the pathway that explains how the gut influences
mood, cognition, and mental health, as well as how the brain influences intestinal functions such
as the activity of functional immune effector cells [42,43]. Research has revealed alteration of GBA
in ADHD [44]. Clinical data indicate that psychological stress evokes a weaker activation of the
hypothalamic–pituitary–adrenal axis (HPA) in children with ADHD compared to the control group [45].
Research shows that children with ASD display abnormal gut permeability as measure by the
lactulose/mannitol ratio test when compared to controls [46]. Furthermore, higher serum zonulin has
been associated with social impairment compared to controls [6], indicating that children with mental
disorders are more prone to increased IP. A better understanding of the relationship between the GBA
and the neuro-immune system provides a novel approach for the management of mental disorders.
There is an urgent need to investigate these emerging interrelations further. To the authors’ knowledge,
there is no existing systematic review on the association between IP and mental disorders in children.
The aim of this systematic review was to summarize evidence from observational studies on IP,
evaluating intrinsic biomarkers or endotoxins as exposure in children and adolescents diagnosed with
mental disorders.
2. Materials and Methods
This systematic review was conducted and reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines [47] (PRISMA checklist in Appendix A) to
improve both study accuracy and transparency. Relevant experts from different health disciplines joined
the review team for additional quality management, such as for search strategy design, clinical research,
and biostatistics. Every attempt was made to develop a comprehensive protocol with appropriate
literature searches, screening, data extraction, and reporting methodologies, along with detailed
eligibility criteria. The review was preregistered with PROSPERO (162208). Any amendments to the
protocol were dated and detailed rationale for the changes documented in PROSPERO.
2.1. Search Strategy
Selected bibliographic databases for observational studies were searched for this review.
The bibliographic databases include PubMed, Cochrane CENTRAL, PsycINFO, and Web of Science.
Searches were limited to observational study type publications with no language restrictions. A Grey
literature search was performed. A manual search of key journals was performed online. Experts in the
field were contacted for relevant literature on the topic under review. The last search was conducted
in April 2020 but repeated before publication, retrieving one new study which had been published
during the review process. Prior to the main search, the PROSPERO was searched to prevent the
repetition of the review in question. To perform the best possible search for the review, combinations of
free-text and subject headings (for example, Medical Subject Headings [MeSH] in PubMed) were used.
The peculiarities of every database and consequences for the search strategy and the search strings
were considered. Identification of controlled vocabulary terms for each database was attempted by
retrieving studies from the database meeting the inclusion criteria for the review, and common text
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words were noted and the subject terms that the indexers have applied to the studies. The search was
conducted using combinations of the search terms, and a detailed search string was developed. A set
of search terms was designed according to the PICOs criteria. All terms within each concept of PICO
were combined with the Boolean operator “OR” to increase the sensitivity of the search as it expands
the retrieval (detailed sample search string in Appendix B). Search terms were identified by trying out
ClinicalTrials.gov, amongst other things. Unless otherwise stated, search terms were free-text terms.
Details of the date of the last search and database searched were also documented in addition to the
period searched and an outline of the initial search results.
2.2. Eligibility Criteria
Included studies were limited to human observational studies. In identifying the review question
and developing the eligibility criteria, PICO was used as a guide [48]. Population studies on children
and adolescents (0–18 years), diagnosed with one or more of the following according to validated
criteria; anxiety disorders (AD), ASD, attention deficit disorder (ADD), ADHD, bipolar disorder (BD),
major depressive disorder (MDD), manic-depressive disorder, OCD, and schizophrenia (SCZ). Mental
disorders, diagnosed by a standard procedure such as experts’ diagnoses involving dimensional and
multi-informant assessments, including standardized diagnostic instruments and validated rating
scales, were eligible for inclusion. In addition, the study needed to address intestinal permeability.
The exposures were biomarkers (intrinsic or endotoxins) for intestinal permeability such as zonulin,
diamine oxidase (DAO), lipopolysaccharide (LPS), and lipopolysaccharide binding protein (LBP) in
individuals diagnosed with one or more of the mental illnesses according to the validated criteria.
Comparators were the same biomarkers (intrinsic or endotoxins) for intestinal permeability (Table 1).
Table 1. Inclusion criteria based on the PICO method.
Population
Children (0–18 years) diagnosed with one or more of the following according to
validated criteria; anxiety disorders (AD), autism spectrum disorder (ASD),
attention deficit disorder (ADD), attention deficit and hyperactivity disorder (ADHD),
bipolar disorder (BD), major depressive disorder (MDD), manic-depressive disorder,
obsessive–compulsive disorder (OCD), and schizophrenia. Mental disorders should be
diagnosed by a standard procedure such as experts’ diagnoses involving dimensional
and multi-informant assessments, including recognized and validated rating scales.
To be eligible for inclusion, the study also needed to address intestinal permeability.
Exposures
Biomarkers (intrinsic or endotoxins) for intestinal permeability such as zonulin,
diamine oxidase (DAO), lipopolysaccharide (LPS), and lipopolysaccharide binding
protein (LBP) in individuals diagnosed with one or more of the mental illnesses
according to the validated criteria.
Comparison
Biomarkers (intrinsic or endotoxins) for intestinal permeability such as zonulin,
diamine oxidase (DAO), lipopolysaccharide (LPS), and lipopolysaccharide binding
protein (LBP) in controls.
Outcome
Comparing intestinal permeability values (serum zonulin, stool zonulin, serum
diamine oxidase, serum LPS, or serum LPB) between children diagnosed with mental,
behavioral, or neurodevelopment disorders and controls.
2.3. Data Management
A study flow diagram was developed based on the PRISMA statement and flow diagram
principle [47]. This was done in order to illustrate the results of the search/research and the process by
which the records were screened and selected for the review. Results from the search were imported
directly into the reference management system EndNote. All studies were screened for relevance using
the full citation, abstract, and indexing terms before excluding studies as not relevant. Duplicates were
removed, and the most recent and complete version of the studies was reviewed. All relevant studies
were assessed for eligibility by three reviewers, B.A., as well as E.A. and H.S., splitting their part in
two, according to the pre-specified inclusion and exclusion criteria.
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2.4. Selection and Data Collection Process
The data was extracted by the reviewers using a predefined data extraction form (Appendix C).
The data extracted included specific details about the patients, exposures, setting, and outcomes based
on PICO. For missing information from the included studies, published reports of the individual
studies were accessed, and authors were contacted for clarification or further information [49].
Studies, including relevant data/information but not fulfilling inclusion criteria were retained for later
use, e.g., in the introduction/discussion chapters. The predefined data extraction form used to collect
relevant information from each study included (but was not limited to) the following: Reviewer ID,
date of extraction, general information (i.e., author details, title, citation, year of publication, source of
funding/conflict of interest, doi/url), study characteristics (i.e., objective, limitations, inclusion-/exclusion
criteria, types of participants, diagnosis), population (i.e., eligibility criteria, age, male/female
proportion, prior treatment history), participant characteristics (i.e., age, gender, disease characteristics,
diagnostic criteria), exposure/comparison and setting (i.e., biomarkers, comparator (unclear or
none), number and type of clinical settings), outcome data/results (i.e., main outcome and effects
addressed in the study, changes in the intestinal permeability, metabolic parameters and biomarkers,
total number of participants included in the study), statistical techniques used, number of participants
involved in analysis, and summary outcome data (i.e., dichotomous, continuous, estimate of) and
outcome measures.
2.5. Quality Assessment and Risk of Bias Tool
All included articles were checked against the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guideline by the lead researcher (BA). The STROBE was not applied
for rating the studies but rather to investigate the author’s adherence to the guidelines in presenting
their work, as the guidelines are not to act as a validation tool for the conducted study [50].
The risk of bias was assessed by the first author (B.A) as well as other reviewers (E.A., H.S.),
according to the Newcastle–Ottawa Scale (NOS) assessing selection, comparability, exposure,
and outcome and rated according to the criteria. This was based on the global evaluation of
the study and informed by the NOS criteria [51]. The full NOS criteria are illustrated in Appendix D.
2.6. Meta-Analysis
Quantitative synthesis was undertaken on studies including the same exposure and outcome,
and mean and standard deviation were pooled, taking into account both within-study and
between-study variability. For the zonulin data, a fixed-effects model was applied, using Cohens-d to
calculate the effect size.
3. Results
3.1. Identification and Description of the Studies
The electronic search of PubMed, Cochrane CENTRAL, PsycINFO, and Web of Science identified
833 records. No references were identified in reference searching. Forty-four records were removed as
duplicate leaving 789 remaining. Altogether, 776 were excluded from the title and abstract screening,
leaving 13 records. Nine studies were excluded with reasons (Table 2), while the remaining four studies
were included in the systematic review. One additional study was retrieved through a second search
performed in May 2020, before publication and was added to the review. Out of the five included
studies, four were included in a meta-analysis, since in the fifth one, only one peptide of the zonulin
peptides family was evaluated. The study flow diagram, according to the PRISMA guidelines [47],
showing the flow of the articles through the selection process, is illustrated in Figure 1.
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Figure 1. PRISMA flow diagram illustrating the results of the search, the process of screening, and the
selection of the records for inclusion in the systematic review and meta-analysis.
Table 2. Description of all excluded studies upon full-text review with reference I.D.
Reference ID Study Characteristics Reason for Exclusion
Calarger et al.,
2019 [52]
Intervention study, major depressive disorder,
children (age: 12–17), n = 41, analyzed urine;
lactulose/mannitol recovery ratio.
Did not fulfill a priori inclusion




Intervention study, ASD, children (age:
10–14), n = 103, analyzed urine;
lactulose/mannitol recovery ratio.
Did not fulfill a priori inclusion






Schizophrenia, children, adolescents, young
adults (age: 8–35), n = 97, analyzed serum; 25
(OH) D, anti-LPS antibodies, CRP, IL-6 levels).
Did not fulfill a priori inclusion
criteria for participants (children
0–18 years).
De Santis et al.,
2019 [55]
Observational pilot study, ASD, children (age:
2–9), n = 110, analyzed mycotoxins.
Did not fulfill a priori inclusion




Research study, ASD, children (age: 0–8), n =
53, analyzed urine; p-cresol levels.
Did not fulfill a priori inclusion
criteria for study type, no controls.
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Table 2. Cont.
Reference ID Study Characteristics Reason for Exclusion
Iovene et al.,
2017 [57]
Intervention study, ASD, children (age: 3–9
approx.), n = 80, analyzed urine;
lactulose/mannitol recovery ratio.
Did not fulfill a priori inclusion




Intervention study, ASD, and DPI children,
young adults, adults (age: 1–20), n = 209,
analyzed; response to an elimination diet.
Did not fulfill a priori inclusion
criteria for study type.
Lau et al.,
2013 [59]
Cohort study, ASD, children (age: 4–12) n =
140, analyzed serum; IgG and IgA antibodies
to gliadin.




Observational cross-sectional study, ASD,
children (age: 2–10), n = 268, analyzed urine;
lactulose/mannitol recovery ratio.
Did not fulfill a priori inclusion
criteria for study type.
3.2. Description of Excluded Studies
The description of the excluded studies and reasons for exclusions are given in Table 2. The most
common reason for exclusion was not fulfilling the inclusion criteria for the review, e.g., not clearly
defined PICO (population, exposure, comparison, outcome) criteria or one of the PICOs criteria not
fulfilling the inclusion criteria for the current systematic review. There were relatively few studies on
children evaluating intrinsic biomarkers or endotoxins as exposure; the more commonly used method
was lactulose/mannitol test, resulting in only 14 studies eligible for full-text review.
3.3. Summary of Main Results and Description of the Studies
For the pre-specified objective for this systematic review, there were five studies eligible,
i.e., five case-control studies [5–9], with all patients diagnosed with mental disorders, compared
to healthy controls and with the majority of recruited participants being males. The full characteristics
of the included studies are shown in Table 3. One of the five studies included investigated the
association between intestinal barrier function, immune response, and ADHD [5]; three investigated
the association between impaired IP, immune responses, and serum zonulin/plasma haptoglobin levels
and ASD [6–8]; and one investigated serum zonulin and claudin-5 levels in OCD [9].
Summary of main findings are listed in Table 4, and a summary of population characteristics and
summary of participant’s characteristics are listed in Tables S1 and S2, respectively. Metabolic parameters
and biomarkers are listed in Table S3. Four [5–7,9] out of five studies analyzed only blood samples,
and one study [8] analyzed both blood and stool samples. Özyurt et al. [5] compared 40 subjects
diagnosed with ADHD to 41 healthy controls. Esnafoglu et al. [6] compared 32 subjects diagnosed with
ASD to 33 healthy controls. Józefczuk et al. [7] compared 75 subjects diagnosed with ASD to 46 healthy
controls. Rose et al. [8] compared 46 subjects diagnosed with ASD (with or without current or previous
GI symptoms) to 41 healthy controls (with or without current or previous GI symptoms). Işık et al. [9]
compared 24 subjects diagnosed with OCD to 24 healthy controls. The mean age of the included
participants diagnosed with ASD and ADHD was seven and eight years, respectively, and 14 years in
patients diagnosed with OCD Four studies [5–7,9] analyzed serum zonulin, and one study [8] analyzed
plasma haptoglobin levels and was, therefore, not included in the meta-analysis.
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Table 3. Summary of the characteristics of the included case-control studies.
































46 ASD (NoGI: 26, GI: 20),
41 TD (NoGI: 35,
GI:6; Total Stool (91).
50 ASD (NoGI: 29, GI: 21),























N/A: Not available, ASD: autism spectrum disorders, ADHD: attention deficiency hyperactivity disorder, OCD: obsessive–compulsive disorder, HC: healthy controls, CSA: celiac-specific
antibodies, AGA: anti-gliadin antibodies. ADI-R: Autism Diagnostic Interview-Revised, ADOS: Autism Diagnostic Observation Schedule, DuPaul ADHD-RS-IV Inventory: DuPaul
attention deficit hyperactivity disorder rating inventory, CARS: Childhood Autism Rating Scale, K-SADS-PL: Kiddie Schedule for Affective Disorders and Schizophrenia, DSM-5: DSM-5:
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, CY-BOCS: Children’s Yale–Brown Obsessive–Compulsive Scale, MOCI: Maudsley Obsessive–Compulsive Inventory,
RCADS-CV: Revised Child Anxiety and Depression Scales–Child Version, BMI: Body Mass Index, I-FABP: Intestinal fatty acid binding protein. ASD—GI: with ASD and GI symptoms of
irregular bowel habits, ASD—NoGI: with ASD but without current or previous GI symptoms, TD-GI: typically developing children with GI symptoms, TD-NoGI: typically developing
children but without current or previous GI symptoms.
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Table 4. Summary of main findings.
First Author, Year of
Publication, Country
Participants Included in the
Study Based on Serum Zonulin
and Plasma Haptoglobin
Main Study Findings Authors Conclusions
Özyurt et al., 2018,
Turkey [5]
81
Children with ADHD had significantly elevated
levels of zonulin compared to controls. Children
with hyperactive/impulsive presentations had
significantly elevated zonulin compared to other
presentations. ADHD symptoms and social
communication problems correlated significantly
with zonulin levels, and hyperactive/impulsive and
social communication symptoms were important
predictors of zonulin levels.
“Regardless of its limitations, the results of our study suggest that
zonulin levels may be elevated in children with ADHD (especially
the hyperactive/impulsive presentation) and that this elevation
correlated with social deficits. Symptoms of
hyperactivity/impulsivity and social deficits independently predict
zonulin levels in children with ADHD although the changes in
adjusted R2 suggest that the majority of the predictive value lies
with symptoms of hyperactivity/impulsivity.”
Esnafoglu et al., 2017,
Turkey [6] 65
There was an increase in serum zonulin levels in the
group with ASD compared with the healthy control
group. Additionally, for all subjects, there was a
positive correlation identified between the CARS
score, indicating severity of autism, and zonulin.
“Increased zonulin levels in patients with ASD may play a role in
the development of ASD symptoms. However, zonulin
upregulation and subsequent increase in intestinal permeability
may be necessary but not sufficient to develop ASD, because other
factors are likely at play.”
Józefczuk et al., 2017,
Poland [7] 121
Concentrations of zonulin were the highest in the
youngest children (5 years). The mean level of
zonulin in this group was significantly higher
compared with patients aged 6–11 years. The
occurrence of anti-TG6 antibodies in ASD patients
with normal mucosa was not associated with CD.
“There is a subgroup of ASD patients whichrespond to gluten with
increased production of antibodies against native gluten and
neural TG6, but not of typical celiac-specific antibodies, and this
production is not related to serological markers of an impaired
intestinal barrier.”
Rose et al., 2018,
California [8] 87
Children with ASD who experience GI symptoms
have an imbalance in their immune response,
possibly influenced by or influencing metagenomic
changes, and may have a propensity to impaired gut
barrier function, which may contribute to their
symptoms and clinical outcome.
“We found several differences when comparing children with ASD
who exhibit GI symptoms vs. those that did not. The most notable
of these was the reduced regulatory TGFb1 response of the ASDGI
groups following stimulation. We also noted an increase in the
production of cytokines linked to mucosal inflammation after
TLR-4 stimulation in children with ASDGI symptoms relative to
children with ASDNoGI. Our analysis of the microbiome
underscores the relationship between the presence of GI symptoms
and the host microflora and suggest a possible role of dysbiosis in
the co-morbidity of GI issues in ASD”
Işık et al., 2020, Turkey
[9] 48
There was an increase in serum claudin-5 levels in
the group with OCD compared with the healthy
control group. There was no significant difference
between the study and control group in the serum
zonulin concentrations.
“Regardless of the limitations, taken together with our results,
dysregulation of the BBB, especially claudin-5, may be involved in
the etiology of OCD. Further detailed and more comprehensive
studies designed on a longitudinal basis are greatly needed to find
out exactly whether increased claudin- 5 levels are the cause or
consequence of the disease process in OCD”
ADHD: attention deficit hyperactivity disorder. CARS: childhood autism rating scale. ASD: autism spectrum disorders.TG6: transglutaminase 6. IgA: immunoglobulin A.
IgG: immunoglobulin G. CD: celiac disease. GI: gastrointestinal. OCD: obsessive–compulsive disorder. BBB: blood–brain barrier.
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No studies on the following mental disorders fulfilled the inclusion criteria for the current
systematic review: anxiety disorders, attention deficit disorder, bipolar disorder, manic-depressive
disorder, major depressive disorder, or schizophrenia. The association between IP and mental disorders
was investigated by serum zonulin and plasma haptoglobin, in a total of 402 participants (217 patients
and 185 controls);
• ADHD:
◦ “Increased zonulin is associated with hyperactivity and social dysfunctions in children
with attention deficit hyperactivity disorder” [5].
• ASD:
◦ “Increased serum zonulin levels as an intestinal permeability marker in autistic subjects” [6].
◦ “The occurrence of antibodies against gluten in children with autism spectrum disorders
does not correlate with serological markers of impaired intestinal permeability” [7].
◦ “Differential immune responses and microbiota profiles in children with autism spectrum
disorders and co-morbid gastro-intestinal symptoms” [8].
• OCD:
◦ “Serum zonulin and claudin-5 levels in children with obsessive–compulsive disorder” [9].
Serum zonulin was assessed in four studies [5–7,9], including 171 patients and 144 controls,
and they are listed in Table 5. One study, Rose et al. [8], only reported plasma haptoglobin levels but
not serum zonulin levels, which was confirmed through author contact (plasma haptoglobin levels are
listed in Table S4) and therefore not included in the meta-analysis.
Table 5. Serum zonulin levels (ng/mL) in patients and control groups.
Study
Serum Zonulin Levels (ng/mL) in Patients and Control Groups
Patient Group Control Group
n Mean Zonulin S.D. n Mean Zonulin SD p-Value
Özyurt et al., ADHD
(n)/(ng/mL), mean ± SD 40 105.36 98.38 41 63.34 73.4 0.031
Esnafoglu et al., ASD
(n)/(ng/mL), mean ± SD 32 122.3 98.46 33 41.89 45.83 <0.001
Józefczuk et al., ASD




ş ık et al., OCD (n)/(ng/mL),
mean ± SD 24 98.93 83.06 24 103.7 73.53 0.834
3.4. Study Quality
Using the quality assessment tool, four articles were identified as strong and one as moderate.
The risk of bias assessment of the included studies is summarized in Table 6.
All the studies got a full quality score for six of the nine parts of the quality assessment. The
reason for not receiving a full quality score for selection of controls was that the controls were recruited
in a hospital setting, or recruiting was not explained at all. To be eligible for a point for non-response
rate, the same rate of exposure had to be mentioned for both cases and controls.
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Response Rate Final Score
Özyurt et al., ADHD [5] 0 * * 8/9 (strong)
Esnafoglu et al., ASD [6] 0 * * 8/9 (strong)
Józefczuk et al., ASD [7] 0 0 0 6/9 (moderate)
Rose et al., ASD [8] * * 0 8/9 (strong)
Işık et al., OCD [9] 0 * 0 7/9 (strong)
One “*” means one point, “0” means no point.
3.5. Meta-Analysis
Data were synthesized based on the outcome measure, i.e., biomarkers of intestinal permeability
equating ADHD, ASD, and OCD, as mental disorders. Information on zonulin levels in cases and
healthy controls (mean and standard deviation) was extracted from the four publications that reported
such numbers [5–7,9]. Meta-analysis was conducted using Meta-Essential [61]. Study findings were
combined using a fixed-effect model, and the effect size was expressed as Cohen’s d, effect size
small-medium (d = 0.3–0.4) (Figure 2). Based on these four studies, the statistical heterogeneity was
estimated as high evaluated using a fixed-effect model (I2 71.52%). However, as the number of studies
is only four, the true underlying heterogeneity is difficult to assess accurately [62]. Based on the Egger
test for funnel asymmetry, no indication of publication bias was observed (p = 0.72). The combined
estimate from the studies presented in Table 5 showed a statistically significant difference (p = 0.001)
between zonulin levels among cases (171) compared to controls (144). In one of the studies included in
the pooled estimate, Józefczuk et al., [7] the measured zonulin levels were much lower compared to the
other three studies (levels in cases 17.2 ± 15.7 ng/mL and 15.3 ± 5.9 ng/mL in healthy controls, p > 0.05).
Figure 2. Forest plot showing the individual mean differences among cases and controls for each of
the four studies and the combined estimate from a fixed-effect model (bottom, p = 0.001). The Effect
estimates are presented as Cohen’s d with positive effect size indicating higher zonulin levels among
cases compared to controls.
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4. Discussion
The aim of this systematic review was to summarize the evidence on IP in children diagnosed
with mental disorders. The main findings demonstrate that there is an association between increased
plasma zonulin levels and impaired intestinal barrier function in ADHD and ASD but not as much in
OCD. However, serum plasma levels of claudin-5, a tight-junction protein in the blood–brain barrier,
were found to have severely increased in OCD patients. Performing the meta-analysis, on the four
studies using the mean zonulin plasma levels of patients and control groups from four [5–7,9], revealed
a significant difference between the groups (p = 0.001). However, Józefczuk et al. [7] reported very low
mean serum zonulin levels (17.2 ± 15.7 ng/mL in cases and 15.3 ± 5.9 ng/mL in healthy controls) in
both patients and control groups which may be explained by possible issues with their assessment
kit in terms of sensitivity [63]. The fifth study included in the systematic review, Rose et al. [8],
was excluded in the meta-analysis as they did not report findings on serum zonulin levels but plasma
haptoglobin levels.
The inclusion criteria for this systematic review were strict, and studies were only included if
patients were diagnosed with mental disorders according to a standard diagnostic procedure such as
experts’ diagnoses involving dimensional and multi-informant assessments, including recognized and
validated rating scales. The quality of the included studies was rated strong [5,6,8,9] and moderate [7],
respectively. However, none of the authors reported following the STROBE guideline in presenting
their work.
The five included case-control studies assessed in total 402 children and adolescents, males
(n = 186 cases), and females (n = 95 cases), but predominantly males, i.e., n = 186/95, respectively,
excluding one study [8] as male/female proportion was not reported. Despite the differences between
included studies, i.e., ADHD, ASD, and OCD, there was some overlap between ASDs and ADHD at the
symptom level (social problems) as well as syndrome levels. Both ADHD and ASD have been linked
to the atypical allocation of attentional resources, atypical performance monitoring, atypical processing
of faces, and atypical early sensory processing in both visual and auditory domains. However, there
are also atypical processing aspects that are disorder-specific [64–67].
Özyurt et al.’s [5] was the only study that fulfilled the inclusion criteria for IP And ADHD for the
review, indicating few studies on the topic. There were significantly elevated levels of zonulin in ADHD
compared to controls, and subjects with hyperactive/impulsive presentations had significantly elevated
zonulin compared to children with other presentations. The level of zonulin was independently
predicted by hyperactivity symptoms and Social Responsiveness Scale (SRS) scores in regression
analysis, concluding that serum zonulin may be a biomarker for hyperactivity symptoms and social
difficulties in ADHD [5]. Research shows that symptoms of inattention, hyperactivity, and impulsivity
are all present in ADHD and can lead to severe problems in academic and social fields. Other symptoms
are frequently seen, such as problems with social cues and difficulties in interpreting or respond
appropriately to social situations [64].
Three studies fulfilled the inclusion criteria for the association of IP in ASD patients [6–8].
Esnafoglu et al. [6] identified a correlation between the Childhood Autistic Rating Scale (CARS) score,
indicating the severity of autism, and the level of zonulin, but this was not observed in healthy control
subjects. There was no correlation between age and zonulin levels. However, there were high zonulin
levels detected in some healthy control group subjects indicating other factors contributing to the
ASD pathogenesis.
Józefczuk et al. [7] found a statistically significant negative relationship between age and
concentration of zonulin in another study of IP in ASD. However, this group physiologically had an
immature intestinal barrier because of the young age [68]. In previous research, GI symptoms have
commonly been observed in patients with ASD. They are more common when compared to typically
developing (TD) children, particularly altered bowel habits such as constipation and chronic abdominal
pain, and this seems to correlate strongly with the severity of their ASD, suggesting these co-morbidities
require attention [69–72]. When compared to TD children, children diagnosed with ASD are more
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likely to have at least one frequent GI symptom, which can be defined as gaseousness, constipation,
painful bowel movement, diarrhea, or recurring abdominal pain. In addition, these subjects generally
score worse on irritability, social withdrawal, stereotypy, and hyperactivity compared with children
having no frequent GI symptoms [72].
Rose et al. [8] reported alterations in plasma haptoglobin levels in ASD subjects compared to
controls as well as dysbiotic microbiota in fecal samples. Findings from this review suggest that children
with ASD and GI symptoms have an imbalanced immune response resulting in a predisposition
to impaired barrier function, which may contribute to their symptoms and clinical outcome [8].
Therefore, impaired intestinal barrier function may be a marker of ASD only in children with ASD and
GI problems [8].
Işık et al.’s [9] was the only article that fulfilled the eligibility criteria for OCD and IP for this
review. Concentrations of serum zonulin and claudin-5 levels were compared between OCD patients
and healthy controls. The association between zonulin and claudin-5 concentrations and OCD severity
were investigated, and serum claudin-5 levels were found to be significantly higher in OCD patients.
However, serum zonulin levels were not significantly different between the groups, which could
indicate different mechanisms compared to ADHD, ASD, as well as other types of mental disorders.
The nine excluded studies upon full-text review, not fulfilling the inclusion criteria for the
review [52–60], included three types of mental disorders, i.e., major depressive disorder, schizophrenia,
and ASD. All of the studies were in children, except one including children and adults up to 35 years [54].
The most common reason for exclusion was the use of lactulose/mannitol test and no assessment
of intrinsic biomarkers nor exotoxins. However, the findings supported a mechanistic pathway
linking the sympathetic nervous system activation to increased IP as involving activation of the
immune system [52]. Moreover, findings from Delaney et al. [54] revealed a potential interrelated
inflammatory contribution to the pathophysiology of psychosis. Iovene et al. [57] found low/mild
intestinal inflammation as well as increased IP together with the presence of GI symptoms in ASD
subjects compared to controls, and Jyonouchi et al. [58] found innate immune response against LPS in
ASD subjects. Lau et al. [59] reported that ASD children had significantly higher levels of IgG antibody
to gliadin compared with unrelated healthy controls. They concluded increased GI symptoms pointed
to mechanisms involving immunologic abnormalities and increased IP in a subset of ASD children.
On the other hand, Dalton et al. [53] and Pusponegoro et al. [60] found no difference in IP between
ASD children and controls. According to De Santis et al. [55], the comparison of average values of
increased IP among groups, i.e., ASD and controls, did not produce statistically significant differences,
and Gabriele et al. [56] did not report increased IP in ASD infants. Therefore, though not included in
the current systematic review and meta-analysis, five of the studies, including children diagnosed with
ASD, one research on major depressive disorder, and one study on schizophrenia, support the findings
from this systematic review and meta-analysis.
Clinical and animal model studies of the association between intestinal barrier function and
mental disorders have been reviewed, with the majority of reports on ASD and schizophrenia [46].
Research shows that children with ASD display abnormally high urinary excretion of the sugars used as
permeability markers, i.e., in the lactulose/mannitol ratio test when compared to controls [46]. Data from
90 ASD children as well as 146 relatives showed that 36.7% of ASD patients displayed an abnormal
intestinal permeability (lactulose/mannitol ratio) when compared with 21.2% of their first-degree
relatives (versus 4.8% of adult controls and none of the healthy child controls) [46]. Fiorentino et al.
analyzed postmortem brain tissues as well as duodenal tissue samples from ASD subjects revealing
impaired gut barrier integrity as well as expression of genes associated with impaired blood–brain
barrier integrity coupled with increased neuroinflammation [11]. Besides, intestinal barrier defects in
the zonulin transgenic mouse model (ZTM) seem to have a critical effect on the intestinal microbiota
composition, i.e., dysbiosis, as well as the immune system [73].
Latent pro-inflammatory status is created from uncontrolled trafficking of microbial products,
which leads to skewed microbiota composition and immune profile. When challenged by an environmental
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trigger, the onset of overt inflammation can be produced with an increased risk of developing chronic
disease [19,73]. Intestinal dysbiosis, including various metabolites, has been demonstrated both in animal
models of ASD and in ASD children [74]. Intestinal dysbiosis could contribute to the low-grade systemic
inflammatory state frequently reported in subjects with GI co-morbidities [74].
According to Hadjivassiliou et al., anti-neural TG6 antibodies are better serological markers
of gluten intolerance in subjects with neurological symptoms than antibodies against intestinal
TG2 [75]. In this review, occurrence of antibodies against neural anti-TG6 in ASD patients were found,
which demonstrates a subgroup of ASD patients that responded to gluten with increased production of
antibodies against native gluten and neural TG6 antibodies but not of typical celiac-specific antibodies.
However, this production was not related to serological markers of increased IP [7].
A combination of increased IP and chronic inflammation may affect brain function and are
associated with higher global psychiatric symptoms [12,76]. Disrupted homeostasis in the gut,
i.e., dysbiosis, contributes to translocation of potential harmful pathogens via the enteric nervous
system (ENS) and the vagal nerve from the gut to the brain [77]. The digestive tract interacts with the
external environment, including the microbiota. The role of the intestines is to be selectively permeable
for the intestinal luminal contents that will pass through the mucosal layer and affect the enteric
ganglions before entering the systemic circulation where it will affect the central nervous system [15,78].
It is well established that the microbiome, i.e., the genetic material of the microbes, can significantly
affect mental health, i.e., emotions and cognitive function. The HPA axis is sensitive to the microbiome,
and research shows that modification of the intestinal microbiota by re-establishing intestinal eubiosis
can alter HPA responsiveness [78,79].
Increased activity in the HPA axis has been observed in OCD subjects compared to controls [80].
Clinical evidence has been provided on alteration in microbiota diversity and complexity compared to
controls, i.e., in ASD [81–86], ADHD [8,87], anxiety disorders, bipolar disorder [88,89], depression and
schizophrenia [90–94], as well as in stress [95]. Microbiota affects intestinal integrity, and dysbiosis can
lead to intestinal barrier dysfunction, which may trigger the immune system, affecting the nervous
system [96]. While several studies have reported an altered microbiota in individuals with ASD,
schizophrenia, or ADHD, there is limited or no evidence to demonstrate whether targeting the
microbiota through probiotics or dietary interventions can improve symptoms in children. A limited
number of studies investigating the therapeutic role of probiotics in individuals suffering from mood
disorders, including stress, anxiety, bipolar disorder, and depression have been conducted to date.
The microbiota–gut–brain axis might provide novel targets for the prevention and treatment of mental
and neuropsychiatric disorders. However, further studies are required to substantiate the clinical use
of probiotics and prebiotics.
According to this systematic review, pathologic findings such as inflammation of the GI system
were common in subjects diagnosed with mental disorders, as well as reduced digestive enzyme
activity and dysbiosis [6–8]. Furthermore, zonulin upregulation and subsequent increase in impaired
barrier function in genetically susceptible individuals may lead to mental disorders. Therefore zonulin
upregulation may be necessary but not sufficient to develop ASD, because other factors are likely to
play a role [27]. Based on these observations, two subtypes of ASD could be considered, with different
grades of inflammation, which might play a role in the etiopathogenesis of ASD and may explain
the conflicting results of studies on dysbiosis and ASD [97,98]. The findings indicate that children
diagnosed with ASD are more prone to inflammation in the gut when GI symptoms are included.
All three studies on ASD and IP in the systematic review add to the knowledge of how impaired barrier
function affects subjects diagnosed with ASD. Furthermore, to explain etiology in ADHD subjects
and to provide additional information on potential therapies, further studies are needed on social
communication skills and zonulin levels in patients diagnosed with ADHD. However, the findings on
serum zonulin levels in OCD subjects revealed no difference compared to controls suggesting possible
different mechanisms to be confirmed in further detailed studies.
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The results from the meta-analysis from this systematic review, revealed a significant difference
between the patient and control groups when all three disorders, ADHD, ASD, and OCD were equated
as “mental disorders”, which gives a more extensive comparison with increased sample size [97].
However, these findings need to be interpreted in terms of population and patient characteristics as
well, in this systematic review.
Many studies were excluded from this review. One of the main reasons was not fulfilling a priory
eligibility criterion for biomarkers and reporting findings on altered IP from lactulose/mannitol testing.
To be eligible for the current systematic review, the outcome needed to include the assessment of
intrinsic biomarkers such as zonulin, which participate in the physiological regulation of intercellular
tight junctions in the small intestine [99]. Dysregulation of the zonulin model may contribute to disease
states that involve disordered intercellular communication, including developmental and intestinal
disorders [5–7,9,17,27,29,100].
The findings of this systematic review and meta-analysis should be weighed against certain
limitations. Eligibility criteria were limited to observational study type publications, and only five
papers [5–9] met the inclusion criteria, including only three types of mental disorders, i.e., ADHD,
ASD, and OCD. The findings from the meta-analysis need to be interpreted in terms of population and
patient characteristics. However, and to the authors’ knowledge, there is no existing systematic review
on the association between IP and mental disorders in children or adolescents. Therefore, the findings
from this systematic review and meta-analysis are novel.
5. Conclusions
Three of the five studies included in this systematic review demonstrate an association
between increased serum zonulin levels and impaired intestinal barrier function in mental disorders,
i.e., in ADHD and ASD, and one study on increased plasma haptoglobin levels and impaired IP.
One study reported increased serum claudin-5 levels and increased permeability of the blood–brain
barrier in OCD. Mean zonulin levels, a marker of intestinal permeability, appear to be higher in
children diagnosed with mental disorders compared to controls. However, the epidemiological
evidence is limited, and methodological inconsistencies have been observed. Therefore, more studies
are required in order to advance the field in this research area. Moreover, the efficacy of targeting
the intestinal barrier in the management of neurological and behavioral aspects of mental disorders,
i.e., central nervous systems disorders, has not yet been established and needs further investigation.
Therefore, further studies are required in order to better understand the complex role of barrier
function, i.e., intestinal and blood–brain barrier, and inflammation in the pathophysiology of mental
and neurodevelopmental disorders.
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AD Anxiety Disorders
ADD Attention Deficit Disorder
ADHD Attention Deficit and Hyperactivity Disorder
BD Bipolar Disorder
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GALT Gut-Associated Lymphoid Tissue
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LBP Lipopolysaccharide Binding Protein
MDD Major Depressive Disorder
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OCD Obsessive–Compulsive Disorder
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ZTM Zonulin Transgenic Mouse Model
Appendix A.
Table A1. Prisma Checklist.
Checklist Item Reported on Page
TITLE
Title 1 Identify the report as a systematic review,meta-analysis, or both. 1
ABSTRACT
Structured summary 2
Provide a structured summary including, as applicable:
background; objectives; data sources; study eligibility
criteria, participants, and interventions; study
appraisal and synthesis methods; results; limitations;
conclusions and implications of key findings;
systematic review registration number.
1
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context ofwhat is already known. 2
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Checklist Item Reported on Page
Objectives 4
Provide an explicit statement of questions being
addressed with reference to participants, interventions,





Indicate if a review protocol exists, if and where it can
be accessed (e.g., Web address), and, if available,




Specify study characteristics (e.g., PICOS, length of
follow-up) and report characteristics (e.g., years
considered, language, publication status) used as
criteria for eligibility, giving rationale.
4
Information sources 7
Describe all information sources (e.g., databases with
dates of coverage, contact with study authors to




Present full electronic search strategy for at least one




State the process for selecting studies (i.e., screening,
eligibility, included in systematic review, and, if




Describe method of data extraction from reports (e.g.,
piloted forms, independently, in duplicate) and any




List and define all variables for which data were
sought (e.g., PICOS, funding sources) and any
assumptions and simplifications made.
4/5
Risk of bias in
individual studies 12
Describe methods used for assessing risk of bias of
individual studies (including specification of whether
this was done at the study or outcome level), and how
this information is to be used in any data synthesis.
5
Summary measures 13 State the principal summary measures (e.g., risk ratio,difference in means). N/A
Synthesis of results 14
Describe the methods of handling data and combining
results of studies, if done, including measures of
consistency (e.g., I2) for each meta-analysis.
8/9
Risk of bias across
studies 15
Specify any assessment of risk of bias that may affect
the cumulative evidence (e.g., publication bias,
selective reporting within studies).
11
Additional analyses 16
Describe methods of additional analyses (e.g.,
sensitivity or subgroup analyses, meta-regression), if




Give numbers of studies screened, assessed for
eligibility, and included in the review, with reasons for
exclusions at each stage, ideally with a flow diagram.
6/7
Study characteristics 18
For each study, present characteristics for which data
were extracted (e.g., study size, PICOS, follow-up
period) and provide the citations.
7/8
Nutrients 2020, 12, 1982 18 of 27
Table A1. Cont.
Checklist Item Reported on Page
Risk of bias within
studies 19
Present data on risk of bias of each study and, if
available, any outcome level assessment (see item 12). 10/11
Results of individual
studies 20
For all outcomes considered (benefits or harms),
present, for each study: (a) simple summary data for
each intervention group (b) effect estimates and
confidence intervals, ideally with a forest plot.
11
Synthesis of results 21 Present results of each meta-analysis done, includingconfidence intervals and measures of consistency. 11
Risk of bias across
studies 22
Present results of any assessment of risk of bias across
studies (see Item 15). 11
Additional analysis 23
Give results of additional analyses, if done (e.g.,






Summarize the main findings including the strength of
evidence for each main outcome; consider their
relevance to key groups (e.g., healthcare providers,
users, and policy makers).
12/15
Limitations 25
Discuss limitations at study and outcome level (e.g.,
risk of bias) and at review-level (e.g., incomplete
retrieval of identified research, reporting bias).
12/15
Conclusions 26
Provide a general interpretation of the results in the





Describe sources of funding for the systematic review
and other support (e.g., supply of data); role of funders
for the systematic review.
15
Appendix B. Detailed Search String (PubMed)
((“Intestinal permeability” [All Fields] OR “tight junction*” [All Fields] OR CLDN [All Fields] OR OCLN
[All Fields] OR occluding [All Fields] OR “occluding junctions” [All Fields] OR claudin [All Fields] OR (“zonulin”
[Supplementary Concept] OR “zonulin” [All Fields]) OR “junctional adhesion molecules” [All Fields] OR (“J
Acupunct Meridian Stud” [Journal] OR “J Acad Mark Sci” [Journal] OR “jams” [All Fields]) OR ((“cytoplasm”
[MeSH Terms] OR “cytoplasm” [All Fields] OR “cytoplasmic” [All Fields]) AND (“plaque, amyloid” [MeSH
Terms] OR (“plaque” [All Fields] AND “amyloid” [All Fields]) OR “amyloid plaque” [All Fields] OR “plaque”
[All Fields] OR “dental plaque” [MeSH Terms] OR (“dental”[All Fields] AND “plaque” [All Fields]) OR “dental
plaque” [All Fields]) AND junctional [All Fields] AND complex [All Fields] AND (“proteins” [MeSH Terms]
OR “proteins” [All Fields])) OR ZO [All Fields] OR 7H6 [All Fields] OR symplekin [All Fields] OR cingulin
[All Fields] OR “diamine oxidase” [All Fields] OR DAO [All Fields] OR (“lipopolysaccharides” [MeSH Terms]
OR “lipopolysaccharides” [All Fields] OR “lipopolysaccharide” [All Fields]) OR (“Leadersh Policy Sch” [Journal]
OR “lps” [All Fields]) OR (liposaccharide [All Fields] AND (“carrier proteins” [MeSH Terms] OR (“carrier”
[All Fields] AND “proteins” [All Fields]) OR “carrier proteins” [All Fields] OR (“binding” [All Fields] AND
“protein” [All Fields]) OR “binding protein” [All Fields])) OR LBP [All Fields] OR (“endotoxins” [MeSH Terms] OR
“endotoxins” [All Fields] OR “endotoxin” [All Fields]) OR “gram-negative bacteria” [All Fields]) AND (“mental
disorders”[All Fields] OR “neurodevelopmental disorders” [All Fields] OR “anxiety disorders” [All Fields]
OR (“administration and dosage” [Subheading] OR (“administration”[All Fields] AND “dosage” [All Fields])
OR “administration and dosage” [All Fields] OR “ad”[All Fields]) OR “autism spectrum disorder” [All Fields]
OR (“Arthropod Struct Dev”[Journal] OR “Agron Sustain Dev” [Journal] OR “asd” [All Fields]) OR “attention
deficit disorder”[All Fields] OR “attention deficit and hyperactivity disorder” [All Fields] OR (“attention deficit
disorder with hyperactivity” [MeSH Terms] OR (“attention” [All Fields] AND “deficit”[All Fields] AND “disorder”
[All Fields] AND “hyperactivity” [All Fields]) OR “attention deficit disorder with hyperactivity” [All Fields]
OR “adhd” [All Fields]) OR “bipolar disorder” [All Fields] OR (“Biol Direct” [Journal] OR “bd” [All Fields])
OR “major depressive disorder” [All Fields] OR MDD[All Fields] OR “obsessive compulsive disorder”[All
Fields] OR OCD [All Fields] OR (“schizophrenia”[MeSH Terms] OR “schizophrenia” [All Fields]))) AND
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(children [All Fields] OR children’[All Fields] OR children” [All Fields] OR children”s [All Fields] OR children’a
[All Fields] OR children’car [All Fields] OR children’cotters [All Fields] OR children’diagnostic [All Fields] OR
children’emotional [All Fields] OR children’hospital [All Fields] OR children’mc [All Fields] OR children’pital [All
Fields] OR children’rights [All Fields] OR children’s [All Fields] OR children’s’ [All Fields] OR children’s’hands
[All Fields] OR children’sacademic [All Fields] OR children’sagency [All Fields] OR children’scancer [All Fields] OR
children’scatalgine [All Fields] OR children’sclinic [All Fields] OR children’scrab [All Fields] OR children’shospital
[All Fields] OR children’significantly [All Fields] OR children’sinfectious [All Fields] OR children’smedical
[All Fields] OR children’smemorial [All Fields] OR children’snational [All Fields] OR children’sresearch [All
Fields] OR children’s [All Fields] OR children’t [All Fields] OR children’with [All Fields] OR children, [All Fields]]
AND (“humans” [MeSH Terms] OR “humans”[All Fields])).
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Data Extraction Form
Reviewer ID:





◦ Year of publication:
◦ Source of funding/conflict of interest:




◦ Stated aim of study/objective:
◦ Limitations (if any):
◦ Inclusion criteria:
◦ Exclusion criteria:
◦ Types of participants:
◦ Diagnosis:
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3 Quality assessment of the study
◦ Methodological quality of evidence according to the STROBE statement
• Number of items tems that should be included in reports of observational studies:






• Diagnostic criteria – (Mental health rating scale):
• Unclear:
5 Exposures/comparison
5.1 Exposures (biomarkers, intrinsic, exotoxins etc.)
5.2 Comparison (describe)
◦ Comparator:
◦ Unclear or none:
5.3 Number and type of clinical settings (in which the exposure/comarison is performed/tested):
6 Outcome Data/results
6.1 Main outcomes and effects addressed in the study
◦ Changes in the intestinal permeability:
6.2 Outcomes for which data were reported:
◦ Metabolic parameters and biomarkers:
• Intestinal permeability (serum Zonulin; stool Zonulin; serum diamine oxidase; serum LPS;
serum LBP):
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6.3 Total number of participants included in the study:
7 Statistical techniques used in the study:
8 Number of participants included in analysis in the study -
9 Summary outcome data
◦ Dichotomous -
• Number of events -
• Number of participants -
◦ Continuous
• Mean and standard deviation -
◦ Estimate of
• Relative effect (as 95% CI) -
• Absolute risk -
◦ Main results -
10 Other comments -
Appendix D. The Nos Criteria
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE CASE CONTROL STUDIES
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and
Exposure categories. A maximum of two stars can be given for Comparability.
Selection
(1) Is the case definition adequate?
(a) yes, with independent validation Ø
(b) yes, eg record linkage or based on self reports
(c) no description
(2) Representativeness of the cases
(a) consecutive or obviously representative series of cases Ø
(b) potential for selection biases or not stated
(3) Selection of Controls
(a) community controls Ø
(b) hospital controls
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(c) no description
(4) Definition of Controls
(a) no history of disease (endpoint) Ø
(b) no description of source
Comparability
(1) Comparability of cases and controls on the basis of the design or analysis
(a) study controls for _______________ (Select the most important factor.) Ø
(b) study controls for any additional factor Ø (This criteria could be modified to indicate specific control
for a second important factor.)
Exposure
(1) Ascertainment of exposure
(a) secure record (eg surgical records) Ø
(b) structured interview where blind to case/control status Ø
(c) interview not blinded to case/control status
(d) written self report or medical record only
(e) no description




(a) same rate for both groups Ø
(b) non respondents described
(c) rate different and no designation
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